The European Stroke Organisation (ESO) is delighted to be running the 8th ESO Conference (ESOC 2022) on 4th – 6th May 2022. For the first time, the conference will be held as a hybrid meeting in Lyon, France, providing the opportunity for delegates around the globe to hear about the latest advances from ground-breaking research in cerebrovascular disease, both virtually and in-person.
This year, we look forward to a record number of studies being presented across our three plenary sessions. We will publish daily press releases on these studies and issue pre-recorded video interviews with each of the principal investigators.
Here are just some of the highly anticipated studies due to be covered:
Reperfusion therapies for acute ischaemic stroke
The results from four clinical trials evaluating the effectiveness of Tenecteplase in acute ischaemic stroke will be presented:
- ACT: Alteplase compared to Tenecteplase Randomized Controlled Trial
- NOR-TEST 2 PART A: Tenecteplase versus Alteplase for Management of Acute Ischaemic Stroke
- TASTE-A: The Melbourne Mobile Stroke Unit Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance
- TWIST: Tenecteplase in Wake-Up Ischaemic Stroke Trial
ACTIMIS evaluates glenzocimab, a novel antithrombotic, in combination with reperfusion therapies in acute ischaemic stroke in a multinational, randomized, double-blind placebo-controlled trial.
ATTENTION is a multi-centre randomized controlled trial evaluating endovascular treatment for acute basilar artery occlusion.
AMETIS evaluates sedation versus general anaesthesia in large vessel occlusion thrombectomy in a randomized controlled trial.
Safety of IVC and DOAC: An international collaboration examines the safety of intravenous thrombolysis in patients with ischaemic stroke and recent direct oral anticoagulants intake in a multi-centre retrospective cohort study.